Viatris Inc
$ 15.25
-5.16%
26 Feb - close price
- Market Cap 18,563,832,000 USD
- Current Price $ 15.25
- High / Low $ 16.47 / 15.14
- Stock P/E N/A
- Book Value 13.13
- EPS -3.13
- Next Earning Report 2026-02-26
- Dividend Per Share $0.48
- Dividend Yield 2.99 %
- Next Dividend Date -
- ROA 0.02 %
- ROE -0.21 %
- 52 Week High 16.47
- 52 Week Low 6.60
About
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Analyst Target Price
$14.11
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-07 | 2023-08-07 | 2023-05-08 | 2023-02-27 |
| Reported EPS | 0.67 | 0.62 | 0.5 | 0.54 | 0.75 | 0.69 | 0.67 | 0.62 | 0.79 | 0.75 | 0.77 | 0.67 |
| Estimated EPS | 0.62 | 0.55 | 0.4919 | 0.572 | 0.68 | 0.68 | 0.67 | 0.65 | 0.74 | 0.71 | 0.69 | 0.72 |
| Surprise | 0.05 | 0.07 | 0.0081 | -0.032 | 0.07 | 0.01 | 0 | -0.03 | 0.05 | 0.04 | 0.08 | -0.05 |
| Surprise Percentage | 8.0645% | 12.7273% | 1.6467% | -5.5944% | 10.2941% | 1.4706% | 0% | -4.6154% | 6.7568% | 5.6338% | 11.5942% | -6.9444% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.52 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-18 | 2025-12-15 | 2025-09-15 | 2025-06-16 | 2025-03-18 | 2024-12-13 | 2024-09-13 | 2024-06-14 | 2024-03-18 | 2023-12-15 |
| Amount | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VTRS
2026-02-26 21:38:19
Viatris (VTRS) reported stronger-than-expected Q4 2025 revenue of US$3.7 billion despite a net loss, and affirmed its 2026 dividend policy of US$0.48 per share. The company is focusing on execution, cost savings, and advancing its ophthalmology pipeline. While the steady dividend and revenue guidance offer some reassurance, investors should consider the ongoing net losses and debt.
2026-02-26 18:51:18
Viatris, a major generic drug manufacturer, is expected to achieve durable growth through new product launches and cost savings initiatives. The company is focusing on complex generics to counteract erosion in traditional small-molecule oral tablet markets. This strategy aims to bring stability and broad-based growth starting in 2026, building on momentum from 2025.
2026-02-26 17:51:19
Viatris (VTRS) reported strong fourth-quarter 2025 results, with adjusted EPS of 57 cents and total revenues of $3.7 billion, both surpassing consensus estimates. The company's sales were driven by its Brands segment, particularly in Greater China and Emerging Markets, and the stock saw an increase in pre-market trading. Viatris also provided its 2026 guidance and reported several FDA approvals and submissions.
2026-02-26 15:57:20
Viatris, a pharmaceutical company with a presence in Pittsburgh, announced a restructuring plan that includes a global workforce reduction of approximately 10%. This move is part of the company's efforts to streamline operations.
2026-02-26 14:51:20
Viatris plans to reduce its global workforce by approximately 10% over the next three years, expecting restructuring charges between $700 million and $850 million but aiming for annual savings of $600 million to $700 million. This decision comes after a strategic review and follows efforts to resolve FDA concerns at its Indore plant in India, which caused a $370 million revenue loss. Additionally, the company disclosed a recent fire at its Nashik, India plant, halting production for about two months.
2026-02-26 13:52:24
Viatris Inc. announced that its Board of Directors approved a 2026 dividend policy of 48 cents per share and declared a quarterly dividend of 12 cents per share. This dividend is payable on March 18, 2026, to shareholders of record as of March 9, 2026, marking the sixth consecutive year the company has paid a dividend. The company also highlighted its mission to provide access to high-quality medicines globally.
